Five months. That is all it took EyePoint Pharmaceuticals to fully enroll more than 480 participants across two concurrent pivotal trials, a pace that reflects genuine demand from retinal specialists and patients who are clearly willing to bet on a fundamentally different mechanism for treating diabetic macular edema. Enrollment speed in ophthalmology trials is rarely a headline, but here it signals something real: investigator confidence in a delivery platform that operates on a six-month re-dosing schedule rather than the monthly or bimonthly injection burden patients currently accept as routine.
The two trials, COMO and CAPRI, share the same architecture: global, randomized, double-masked, and designed as non-inferiority studies with on-label 2 mg aflibercept as the active comparator. The primary endpoint in both is change from baseline in best-corrected visual acuity. Non-inferiority against aflibercept is the correct bar to set, because the commercial argument for DURAVYU (vorolanib intravitreal insert 2.7 mg) is not superior efficacy but radically reduced treatment frequency. Vorolanib is a selective tyrosine kinase inhibitor delivered intravitreally as a sustained-release insert, which means the drug works through a different molecular pathway than anti-VEGF antibodies and avoids the pharmacokinetic cliff that causes monthly injections to become a permanent fixture in a DME patient’s life.
The competitive backdrop has grown more complex. Roche’s Susvimo (ranibizumab injection) was approved as a continuous-delivery option for DME capable of maintaining vision with as few as two treatments per year, and multiple aflibercept 2 mg biosimilars entered the market in 2024. EyePoint is not entering an empty field. What it is doing is making a structural bet that a TKI-based insert with a six-month re-dosing cadence occupies a distinct clinical and commercial position from both port-delivery antibody systems and the growing biosimilar pool. Whether the data validate that bet depends entirely on what the COMO and CAPRI readouts show.
The single number to track from here is the non-inferiority margin on best-corrected visual acuity change. If vorolanib clears that threshold cleanly, the delivery platform becomes the story. If it misses by even a modest amount, no amount of dosing convenience rescues the program.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
